Adaptive Biotechnologies Corporation Common Stock

Day range

$25.24 – $26.45

Open

$25.66

Prev close

$25.51

Volume

488.3K

Market cap

$4.07B

Shares out

159.6M

P/E

—

P/S

13.21

P/B

28.49

P/FCF

—

ROE

-44.7%

ROA

-10.0%

Debt/Equity

2.34

Div yield

0.00%

As of Oct 23, 2026

• Executive officer departureJul 29, 2026

  On July 24, 2026, the Company's Chief Scientific Officer and Co-founder, Dr. Harlan Robins, decided to transition into a strategic consultant role with the Company. The Company expects to enter into a consulting agreement with Dr. Robins on its standard form pursuant to which he would support research and development efforts for the minimal residual disease business and the separation of the immune medicine business.

• Deal terminationJun 22, 2026

  On June 22, 2026, the Company used $156.9 million of proceeds from the Notes offering to repurchase all Revenue Interests and repay in full all of its obligations under the revenue interest purchase agreement (the "OrbiMed Purchase Agreement"), dated September 12, 2022, with OrbiMed Royalty & Credit Opportunities IV, LP.

• Strategic initiativeJun 15, 2026

  Also on June 15, 2026, the Company issued a second press release announcing its intention to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses (the "Business Separation").

• Investor presentationJan 12, 2026

  The Company is furnishing presentation materials (the "Investor Presentation") that management intends to use, possibly with modifications, in one or more meetings from time to time with investors, analysts and others.

• Deal terminationAug 18, 2025

  On August 13, 2025, the Strategic Collaboration and License Agreement between Adaptive Biotechnologies Corporation ('Adaptive') and Genentech, Inc. ('Genentech'), dated as of December 19, 2018 (the 'Agreement'), was terminated, with termination effective February 9, 2026.

Days to cover

4.4

Short interest

11.84M

Avg volume

2.67M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run
  positiveThe Motley Fool· Jul 12, 2026
• Adaptive Biotechnologies Business Separation May Unlock Greater Value
  neutralBenzinga· Jun 17, 2026
• Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
  neutralGlobeNewswire Inc.· Jun 17, 2026
• Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses
  positiveBenzinga· Jun 16, 2026
• Stock Market Today: S&P 500, Nasdaq Futures Fall, Dow Gains Amid US-Iran Deal— SpaceX, Dave And Buster's, Western Digital In Focus (UPDATED)
  positiveBenzinga· Jun 16, 2026